Tesla Is Getting More Desperate to Sell Pricey Model 3 Sedans
Tesla surprised everybody on Thursday by announcing a new $45,000 mid-range version of the Model 3.
Here's What You Need to Know About America's New Defense Titan
Two mid-tier companies are combining to take on the primes. Is the combination worth buying into?
Wall Street Hates These 3 Energy Stocks. Should You Buy Them?
Shares of Enphase Energy, SunPower, and Transocean have a lot of people betting against them.
BPFH earnings call for the period ending September 30, 2018.
The streaming-TV giant put to rest concerns about its membership growth.
DHR earnings call for the period ending September 28, 2018.
TXT earnings call for the period ending September 30, 2018.
Earnings, guidance -- and valuation -- disappoint.
Rising rates were supposed to lift this bank's earnings. That isn't happening.
Which stock is a better bet in an uncertain market?
Google’s decision to charge OEMs leaves the door wide open for Microsoft.
The retailer is one of many trying to take the market share given up by Toys R Us.
We talk to the creators of the ChooseFI website and podcast about how to escape the rat race decades early, and live well, too.
ADTN earnings call for the period ending September 30, 2018.
The pizza giant delivered a quarterly report most restaurant chains would give their eyeteeth for, but it wasn't enough to meet analysts' rosy forecasts.
Buying Flipkart required a material amount of cash, even for a company the size of the world’s biggest retailer.
The big financial institutions earned some decent share price bumps with their latest quarterly reports, but their valuations still look relatively cheap.
Is the government gunning for MoviePass?
After nearly a year of declines, the specialty retailer delivered same-store sales growth last quarter. This could indicate its turnaround plans are finally working.
The legalization of recreational cannabis in Canada is resulting in a spike in sales through some of Shopify's digital storefronts.
Big Blue’s short streak of revenue growth hits a brick wall.
The pipeline giant made progress on all fronts.
Novartis continues its pivot toward specialized medicines by acquiring Endocyte.